Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

An Upcoming Conversation With An Expert - Evaluating PacBio's SMRT Sequencing Technology And Where It Stands Against Competitors In The Genome Sequencing Landscape

|About: Pacific Biosciences of California, Inc. (PACB), Includes: ILMN

We're interviewing Dr Vaughn Cooper - PhD, an evolutionary biologist, microbiologist, and geneticist at the University of Pittsburgh who uses the SMRT Sequencing technology.

This call will take place Tuesday, August 15th, at 11:30am ET.

This Expert Call will help investors gain a better understanding of PACBIO’s (PACB) SMRT technology's impact in the DNA research industry. The call will explore SMRT Sequencing's relevance within the field and explore pros/cons compared to other genome sequencing devices. To add your questions for the expert visit:

Who's the Expert:

Dr Vaughn Cooper - PhD

Institution: University of Pittsburgh

  • Evolutionary biologist, Microbiologist, and Geneticist. Associate Professor Microbiology and Molecular Genetics | Computational and Systems Biology, Director of the Evolutionary Genomics Research Facility, Associate Director Center for Medicine and the Microbiome, and Associate Director Center for Innovative Antimicrobial Therapy at Pitt.
  • Pioneered the study of long-term evolution in bacterial biofilms and has been at the forefront for measuring evolutionary forces acting on mutations and cost-effective, high-throughput sequencing methods.
  • PI of lab and responsible for device procurement; the Cooper Lab has been conducting larger studies re: evolution and systems biology of antibiotic resistance, the evolution of microbial communities during pulmonary infections of persons with cystic fibrosis and during acute infections, and the evolution of cancers as they become resistant to chemotherapy.

Questions Investors Are Asking the Expert:

  1. Please describe your current research and where SMRT Sequencing is involved. How frequently is this technology used in your lab?
  2. PacBio's Sequel System, which is based on the same SMRT technology, is said to have a 7x (1million ZMW reads on a chip) increase in the overall throughput. How much of a difference does this make in your research practice?
  3. What are the demographics of the sequencing industry? Should PacBio compete with a lower throughput fast-turnaround instrument, like Illumina’s MiSeq, aimed at smaller laboratories and the clinical diagnostic market, or do you think it will it stay in the high end niche?
  4. In comparing the current technologies on the market, what are the most important aspects, from your experience; is it faster turnaround times, quality and quantity of data, ease of library preparation?
  5. What are the consumables necessary to run a sequencing operation, and how often do they need replacement? (For example PACB reported that in 2016, close to half of their profits were made on consumables)

If you’re interested in accessing this call on the Genome sequencing landscape and adding your questions for the expert visit here for the Expert Interview Details!

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.